Drug Type Bispecific antibody |
Synonyms IL-2Rβ/γ agonists(Teneobio,Inc.) |
Target |
Mechanism IL-2Rβ agonists(Interleukin-2 receptor beta chain agonists), IL-2Rγ stimulants(Interleukin-2 receptor subunit gamma stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Preclinical | US | 19 Oct 2021 | |
Neoplasms | Preclinical | US | 19 May 2021 |